NCT00597038 - A Phase I/II Study of Dasatinib and Dacarbazine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Metastatic Melanoma

Interventions

DRUG

Dasatinib and Dacarbazine (DTIC)

"Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m\^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m\^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m\^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m\^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m\^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m\^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m\^2."

Trial Locations (2)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

94115

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco